Repeated Multilevel Botulinum Toxin A Treatment Maintains Long-Term Walking Ability in Children with Cerebral Palsy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F12%3A8142" target="_blank" >RIV/00064203:_____/12:8142 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/12:8142

Výsledek na webu

<a href="http://www.csnn.eu/ceska-slovenska-neurologie-clanek/opakovana-viceetazova-aplikace-botulinum-toxinu-a-dlouhodobe-zabranuje-zhorseni-chuze-u-deti-s-detskou-mozkovou-obrnou-38959" target="_blank" >http://www.csnn.eu/ceska-slovenska-neurologie-clanek/opakovana-viceetazova-aplikace-botulinum-toxinu-a-dlouhodobe-zabranuje-zhorseni-chuze-u-deti-s-detskou-mozkovou-obrnou-38959</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Repeated Multilevel Botulinum Toxin A Treatment Maintains Long-Term Walking Ability in Children with Cerebral Palsy

Popis výsledku v původním jazyce

Aims: Botulinum toxin type A (BoNT-A) offers a targeted form of therapy to reduce spasticity and has become a standard form of treatment in children with cerebral palsy (CP). However, the effects of repeated BoNT-A treatment over a longer periods of timeare not well known. We hypothesized that children treated with multi-level, high-dose, repeated BoNT-A applications would not deteriorate in their gait function over a minimum period of four years. Materials and methodology: Gait in 18 children with spastic diplegic CP, mean age 6 years 9 months, Gross Motor Function Classification System I-III, treated according to the concept of integrated BoNT-A application over a minimum of four years was evaluated using the kinematic and kinetic gait analysis. Themain outcome measure was the Gait Deviation Index (GDI). Results: The mean follow-up time was 5 years and 9 months (SD 1 year 5 months). Each child received a mean of 1.02 (SD 0.37) applications of BoNT-A per year. The gait function asse

Název v anglickém jazyce

Repeated Multilevel Botulinum Toxin A Treatment Maintains Long-Term Walking Ability in Children with Cerebral Palsy

Popis výsledku anglicky

Aims: Botulinum toxin type A (BoNT-A) offers a targeted form of therapy to reduce spasticity and has become a standard form of treatment in children with cerebral palsy (CP). However, the effects of repeated BoNT-A treatment over a longer periods of timeare not well known. We hypothesized that children treated with multi-level, high-dose, repeated BoNT-A applications would not deteriorate in their gait function over a minimum period of four years. Materials and methodology: Gait in 18 children with spastic diplegic CP, mean age 6 years 9 months, Gross Motor Function Classification System I-III, treated according to the concept of integrated BoNT-A application over a minimum of four years was evaluated using the kinematic and kinetic gait analysis. Themain outcome measure was the Gait Deviation Index (GDI). Results: The mean follow-up time was 5 years and 9 months (SD 1 year 5 months). Each child received a mean of 1.02 (SD 0.37) applications of BoNT-A per year. The gait function asse

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Česká a slovenská neurologie a neurochirurgie

ISSN

1210-7859

e-ISSN

—

Svazek periodika

75

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

737-741

Kód UT WoS článku

000311242700010

EID výsledku v databázi Scopus

—